How has Intellia Therapeutics's other commercial liabilities changed year-over-year?

Intellia Therapeutics's other commercial liabilities decreased by 7.1% year-over-year, from $40.81M to $37.92M.

What is the long-term trend for Intellia Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), Intellia Therapeutics's other commercial liabilities has grown at a 14.3% compound annual growth rate (CAGR), from $25.55M to $49.86M.

Intellia Therapeutics NTLA Other Commercial Liabilities

Other Commercial Liabilities at other companies

Ionis PharmaceuticalsIONS

——

ALN

Alnylam PharmaceuticalsALNY

——

CRISPR TherapeuticsCRSP

——

Viridian Therapeutics, Inc.VRDN

——

Nektar TherapeuticsNKTR

——

Sarepta Therapeutics, Inc.SRPT

——

Other financials

Income statement

See full

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Balance sheet

See full

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Cash flow

See full

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Valuation

See full

Market cap$2.13B+106%

Enterprise value$2.08B+100%

P/S32.2×+9.5×

Profitability

See full

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Returns & leverage

See full

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Intellia Therapeutics's other commercial liabilities?: Intellia Therapeutics (NTLA) reported other commercial liabilities of $37.92M in Q1 2026.
How has Intellia Therapeutics's other commercial liabilities changed year-over-year?: Intellia Therapeutics's other commercial liabilities decreased by 7.1% year-over-year, from $40.81M to $37.92M.
What is the long-term trend for Intellia Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), Intellia Therapeutics's other commercial liabilities has grown at a 14.3% compound annual growth rate (CAGR), from $25.55M to $49.86M.